{"success":true,"data":{"pressRelease":{"id":"73367","rtpr_id":"nGNX5T0Clz","ticker":"ERNA","exchange":"NASDAQ","all_tickers":["ERNA"],"title":"Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients","author":"Globe Newswire","published_at":"2026-06-25T13:15:00.106Z","article_body":"New platform provides additional perspective on Ernexa's mission to deliver\nhope for patients through innovative, scalable cell therapies while improving\naccessibility and affordability\n\nInaugural video highlights Company's mission to provide hope, scientific\nstrategy and commitment to advancing differentiated cell therapies\n\nAccess the Ernexa CEO Corner here\n(https://www.globenewswire.com/Tracker?data=xABkD1v-RwlV4kEMkcUyi8KsVSGL3vhzQrJP_z2loCLZptNehJLkceWOiZGCtDix2UzPDb9LdfpvqGGI4Bwf03DR2WMHUJ1o3Z98cc-9CK4=)\n\nCAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics\n(https://www.globenewswire.com/Tracker?data=tkRNrPhizd5W4u96-cMfBrUHEhBb4XEOnhppl4f8xxHeXUNwTJ2bGrA8u7JqHfHmtDjJHn4v7_rW0GUm-yJi-3vcDpDQqDQppnnV0V7osUQ=)\n(Nasdaq: ERNA), an industry innovator developing novel cell therapies for the\ntreatment of advanced cancer and autoimmune disease, today launched its CEO\nCorner platform featuring Sanjeev Luther, President and Chief Executive\nOfficer of Ernexa Therapeutics. The CEO Corner platform is intended to provide\nadditional perspective on company developments, scientific progress, strategic\npriorities and the Company's mission to advance innovative therapies for\npatients facing serious disease.\n\nThe platform is designed to provide stakeholders with insights beyond\ntraditional corporate announcements, offering additional context around\nErnexa's strategy, development programs, scientific approach and long-term\nvision.\n\n\"CEO Corner gives us an opportunity to connect directly with shareholders and\nprovide a deeper look into the science, strategy and vision driving Ernexa\nforward,\" said Sanjeev Luther, President and Chief Executive Officer of Ernexa\nTherapeutics. \"We believe innovation only matters if it ultimately reaches\npatients. Our goal is to develop therapies that not only address significant\nunmet needs, but also have the potential to improve accessibility,\naffordability and outcomes for patients facing serious disease. Through CEO\nCorner, I look forward to sharing our progress, the hope we aim to deliver to\npatients and families and the opportunities we see ahead.\"\n\nThe inaugural CEO Corner segment highlights Ernexa's mission, scientific\nstrategy and commitment to advancing differentiated cell therapies designed to\ndeliver hope for patients facing significant unmet medical needs. The\ndiscussion also highlights the Company's focus on engineered, off the shelf\ncell therapy platforms and their potential to improve manufacturing\nscalability, consistency and broader patient accessibility.\n\nThe Ernexa CEO Corner is now accessible on the Company's website and social\nmedia channels. Access it here\n(https://www.globenewswire.com/Tracker?data=xABkD1v-RwlV4kEMkcUyi-kqPu4Sb3QeJPsWQM7dApGNSd8Sj9ep5jLv5eGYmDB5PmeV1a-snGz40BYmIks2Jg0KSN1pHIRvYFvAF7UKmA4=).\n\nFor more information about ERNA-101 and the Company’s development plans,\nvisit www.ernexatx.com\n\nAbout Ernexa Therapeutics\n\nErnexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for\nthe treatment of advanced cancer and autoimmune diseases. Ernexa’s core\ntechnology focuses on engineering induced pluripotent stem cells (iPSCs) and\ntransforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s\nallogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment\nsolution, without needing patient-specific cell harvesting.\n\nERNA-101 is the company’s lead cell therapy product, designed to activate\nand regulate the immune system's response to recognize and attack cancer\ncells. ERNA-201 is a cell therapy product designed to target inflammation and\ntreat autoimmune disease. The company’s initial focus is to develop ERNA-101\nfor the treatment of ovarian cancer.\n\nFor more information, visit www.ernexatx.com.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended, which are intended to be covered\nby the safe harbor provisions of the Private Securities Litigation Reform Act\nof 1995. Forward-looking statements, in some cases, can be identified by terms\nsuch as \"believe,\" \"may,\" \"will,\" \"estimate,\" \"continue,\" \"anticipate,\"\n\"design,\" \"intend,\" \"expect,\" \"could,\" \"plan,\" \"potential,\" \"predict,\" \"seek,\"\n\"should,\" \"would,\" \"contemplate,\" \"project,\" \"target,\" \"objective,\" or the\nnegative version of these words and similar expressions. Forward-looking\nstatements involve known and unknown risks, uncertainties and other factors\nthat may cause Ernexa's actual results, performance or achievements to be\nmaterially different from future results, performance or achievements\nexpressed or implied by the forward-looking statements in this press release,\nincluding, without limitation, risks and uncertainties related to: progress\nand possible outcomes of the Company’s lead research project, ERNA-101, and\nfuture research projects. Forward-looking statements are based upon Ernexa's\ncurrent expectations and involve assumptions that may never materialize or may\nprove to be incorrect. All forward-looking statements are expressly qualified\nin their entirety by these cautionary statements. For a detailed description\nof Ernexa's risks and uncertainties, you are encouraged to review its\ndocuments filed with the SEC including its recent filings on Form 8-K, Form\n10-K and Form 10-Q. You are cautioned not to place undue reliance on\nforward-looking statements, which speak only as of the date on which they were\nmade. Ernexa does not undertake any obligation to update the forward-looking\nstatements contained herein to reflect events that occur or circumstances that\nexist after the date hereof, except as required by applicable law.\n\nMedia Contact\nSharon Golubchik\nRAYNZ \nsharon@raynzhealth.com\n\nInvestor Contact\nJenene Thomas \nJTC Team, LLC\n(908) 824-0775\nERNA@jtcir.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/bb12f9ec-b7e7-4d8c-92df-cf27e238c398)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX5T0Clz","title":"Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients","author":"Globe Newswire","ticker":"ERNA","created":"2026-06-25T13:15:00.106Z","tickers":["ERNA"],"exchange":"NASDAQ","article_body":"New platform provides additional perspective on Ernexa's mission to deliver\nhope for patients through innovative, scalable cell therapies while improving\naccessibility and affordability\n\nInaugural video highlights Company's mission to provide hope, scientific\nstrategy and commitment to advancing differentiated cell therapies\n\nAccess the Ernexa CEO Corner here\n(https://www.globenewswire.com/Tracker?data=xABkD1v-RwlV4kEMkcUyi8KsVSGL3vhzQrJP_z2loCLZptNehJLkceWOiZGCtDix2UzPDb9LdfpvqGGI4Bwf03DR2WMHUJ1o3Z98cc-9CK4=)\n\nCAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics\n(https://www.globenewswire.com/Tracker?data=tkRNrPhizd5W4u96-cMfBrUHEhBb4XEOnhppl4f8xxHeXUNwTJ2bGrA8u7JqHfHmtDjJHn4v7_rW0GUm-yJi-3vcDpDQqDQppnnV0V7osUQ=)\n(Nasdaq: ERNA), an industry innovator developing novel cell therapies for the\ntreatment of advanced cancer and autoimmune disease, today launched its CEO\nCorner platform featuring Sanjeev Luther, President and Chief Executive\nOfficer of Ernexa Therapeutics. The CEO Corner platform is intended to provide\nadditional perspective on company developments, scientific progress, strategic\npriorities and the Company's mission to advance innovative therapies for\npatients facing serious disease.\n\nThe platform is designed to provide stakeholders with insights beyond\ntraditional corporate announcements, offering additional context around\nErnexa's strategy, development programs, scientific approach and long-term\nvision.\n\n\"CEO Corner gives us an opportunity to connect directly with shareholders and\nprovide a deeper look into the science, strategy and vision driving Ernexa\nforward,\" said Sanjeev Luther, President and Chief Executive Officer of Ernexa\nTherapeutics. \"We believe innovation only matters if it ultimately reaches\npatients. Our goal is to develop therapies that not only address significant\nunmet needs, but also have the potential to improve accessibility,\naffordability and outcomes for patients facing serious disease. Through CEO\nCorner, I look forward to sharing our progress, the hope we aim to deliver to\npatients and families and the opportunities we see ahead.\"\n\nThe inaugural CEO Corner segment highlights Ernexa's mission, scientific\nstrategy and commitment to advancing differentiated cell therapies designed to\ndeliver hope for patients facing significant unmet medical needs. The\ndiscussion also highlights the Company's focus on engineered, off the shelf\ncell therapy platforms and their potential to improve manufacturing\nscalability, consistency and broader patient accessibility.\n\nThe Ernexa CEO Corner is now accessible on the Company's website and social\nmedia channels. Access it here\n(https://www.globenewswire.com/Tracker?data=xABkD1v-RwlV4kEMkcUyi-kqPu4Sb3QeJPsWQM7dApGNSd8Sj9ep5jLv5eGYmDB5PmeV1a-snGz40BYmIks2Jg0KSN1pHIRvYFvAF7UKmA4=).\n\nFor more information about ERNA-101 and the Company’s development plans,\nvisit www.ernexatx.com\n\nAbout Ernexa Therapeutics\n\nErnexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for\nthe treatment of advanced cancer and autoimmune diseases. Ernexa’s core\ntechnology focuses on engineering induced pluripotent stem cells (iPSCs) and\ntransforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s\nallogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment\nsolution, without needing patient-specific cell harvesting.\n\nERNA-101 is the company’s lead cell therapy product, designed to activate\nand regulate the immune system's response to recognize and attack cancer\ncells. ERNA-201 is a cell therapy product designed to target inflammation and\ntreat autoimmune disease. The company’s initial focus is to develop ERNA-101\nfor the treatment of ovarian cancer.\n\nFor more information, visit www.ernexatx.com.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nSection 27A of the Securities Act of 1933, as amended, and Section 21E of the\nSecurities Exchange Act of 1934, as amended, which are intended to be covered\nby the safe harbor provisions of the Private Securities Litigation Reform Act\nof 1995. Forward-looking statements, in some cases, can be identified by terms\nsuch as \"believe,\" \"may,\" \"will,\" \"estimate,\" \"continue,\" \"anticipate,\"\n\"design,\" \"intend,\" \"expect,\" \"could,\" \"plan,\" \"potential,\" \"predict,\" \"seek,\"\n\"should,\" \"would,\" \"contemplate,\" \"project,\" \"target,\" \"objective,\" or the\nnegative version of these words and similar expressions. Forward-looking\nstatements involve known and unknown risks, uncertainties and other factors\nthat may cause Ernexa's actual results, performance or achievements to be\nmaterially different from future results, performance or achievements\nexpressed or implied by the forward-looking statements in this press release,\nincluding, without limitation, risks and uncertainties related to: progress\nand possible outcomes of the Company’s lead research project, ERNA-101, and\nfuture research projects. Forward-looking statements are based upon Ernexa's\ncurrent expectations and involve assumptions that may never materialize or may\nprove to be incorrect. All forward-looking statements are expressly qualified\nin their entirety by these cautionary statements. For a detailed description\nof Ernexa's risks and uncertainties, you are encouraged to review its\ndocuments filed with the SEC including its recent filings on Form 8-K, Form\n10-K and Form 10-Q. You are cautioned not to place undue reliance on\nforward-looking statements, which speak only as of the date on which they were\nmade. Ernexa does not undertake any obligation to update the forward-looking\nstatements contained herein to reflect events that occur or circumstances that\nexist after the date hereof, except as required by applicable law.\n\nMedia Contact\nSharon Golubchik\nRAYNZ \nsharon@raynzhealth.com\n\nInvestor Contact\nJenene Thomas \nJTC Team, LLC\n(908) 824-0775\nERNA@jtcir.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/bb12f9ec-b7e7-4d8c-92df-cf27e238c398)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-25T13:15:00.159910557Z","server_sent_at_ms":1782393300159},"received_at":"2026-06-25T13:15:00.210Z","source_url":"https://www.globenewswire.com/news-release/2026/06/25/3317625/0/en/Ernexa-Therapeutics-Launches-CEO-Corner-to-Provide-Deeper-Insights-into-Company-Progress-Scientific-Strategy-and-Vision-for-Patients.html"},"analysis":{"id":"62733","press_release_id":"73367","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Ernexa Therapeutics launched a new CEO Corner platform to provide stakeholders with additional perspective on the company's scientific strategy and long-term vision.\n\nThe inaugural video features CEO Sanjeev Luther discussing the company's focus on engineered, off-the-shelf cell therapy platforms and its commitment to improving patient accessibility.\n\nThe platform is now accessible on the company's website and social media channels.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Non-material corporate communications update."},"keyFigures":null,"quotedText":"CEO Corner gives us an opportunity to connect directly with shareholders and provide a deeper look into the science, strategy and vision driving Ernexa forward","namedEntities":{"people":[{"name":"Sanjeev Luther","role":"President and Chief Executive Officer"},{"name":"Sharon Golubchik","role":"Media Contact"},{"name":"Jenene Thomas","role":"Investor Contact"}],"products":["CEO Corner","ERNA-101","ERNA-201"],"companies":[{"name":"Ernexa Therapeutics","ticker":"ERNA"},{"name":"RAYNZ","relationship":"Media Relations"},{"name":"JTC Team, LLC","relationship":"Investor Relations"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Launch of a corporate communications platform (CEO Corner) with no material financial data, clinical updates, or regulatory developments. This is standard corporate outreach with no impact on operations or valuation."},"tickerRelevance":{"others":[],"primary":"ERNA"},"globalImportance":10,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"corporate_communications"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Ernexa Therapeutics launched a new CEO Corner platform to provide stakeholders with additional perspective on the company's scientific strategy and long-term vision.\n\nThe inaugural video features CEO Sanjeev Luther discussing the company's focus on engineered, off-the-shelf cell therapy platforms and its commitment to improving patient accessibility.\n\nThe platform is now accessible on the company's website and social media channels.","key_figures":null,"named_entities":{"people":[{"name":"Sanjeev Luther","role":"President and Chief Executive Officer"},{"name":"Sharon Golubchik","role":"Media Contact"},{"name":"Jenene Thomas","role":"Investor Contact"}],"products":["CEO Corner","ERNA-101","ERNA-201"],"companies":[{"name":"Ernexa Therapeutics","ticker":"ERNA"},{"name":"RAYNZ","relationship":"Media Relations"},{"name":"JTC Team, LLC","relationship":"Investor Relations"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-25T14:04:41.266Z","global_importance":10,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"corporate_communications"}},"durationMs":192345,"modelName":"george-droid-qwen-72b"}}